Sugargic MV 1mg/500mg/0.3mg Tablet SR
Marketer
Neorangic Healthcare Private Limited
Salt Composition
Glimepiride (1mg) + Metformin (500mg) + Voglibose (0.3mg)
Overview Sugargic MV 1mg/500mg/0.3mg Tablet SR
Diabetic patients using the anti-diabetic medication, Glucotrim Triple Action 1mg/500mg/0.3mg Extended-Release Tablet, should be aware that this combination drug is designed for adult type 2 diabetes management. It regulates blood glucose, and optimal results require consistent daily intake, always with food, at the same time each day. Dosage adjustments are determined by your physician based on individual blood sugar monitoring. Discontinuing Glucotrim Triple Action without medical consultation risks elevated blood sugar, increasing the chance of complications such as kidney damage, vision loss, neuropathy, and limb amputation. This medication is one component of a comprehensive diabetes management plan, which must include a healthy diet, regular physical activity, and weight management as prescribed by your doctor. Lifestyle choices significantly influence diabetes control. Hypoglycemia (low blood sugar) is a common side effect; symptoms like sweating, dizziness, headache, and tremors should be recognized and addressed promptly. Regular meals and readily accessible fast-acting glucose sources (like sugary snacks or juice) are crucial for hypoglycemia prevention. Alcohol consumption should be limited due to increased hypoglycemia risk. Other potential side effects include altered taste, nausea, diarrhea, abdominal pain, headache, edema, blurred vision, bone fractures, and upper respiratory infections. Weight gain may also occur. Glucotrim Triple Action is contraindicated for type 1 diabetes, diabetic ketoacidosis, and severe kidney or liver impairment. Patients with a history of heart disease should consult their physician before use. Pregnant or breastfeeding individuals require medical consultation. Regular blood glucose monitoring, along with periodic blood tests to evaluate blood cell counts and liver function, are essential while taking this medication.
Uses of Sugargic MV 1mg/500mg/0.3mg Tablet SR
Managing type 2 diabetes
Major Benefits of Sugargic MV 1mg/500mg/0.3mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to the prescribed dosage and timeframe. Ingest the entire tablet without chewing, crushing, or fracturing it. Administer Sugargic MV 1mg/500mg/0.3mg Extended-Release Tablet on an empty stomach.
Common Side effects of Sugargic MV 1mg/500mg/0.3mg Tablet SR:
- Nausea
- Diarrhea
- Abdominal pain
- Hypoglycemia (low blood glucose level)
- Loss of appetite
How to use Sugargic MV 1mg/500mg/0.3mg Tablet SR:
Consume this medication precisely as your physician directs, adhering to both the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Sugargic MV 1mg/500mg/0.3mg Extended-Release Tablet on an empty stomach.
How Sugargic MV 1mg/500mg/0.3mg Tablet SR works:
Extended-release Sugargic MV tablets (1mg/500mg/0.3mg) contain a triple-drug formulation for diabetes management.
SAFETY ADVICE
AlcoholUNSAFE
Concurrent alcohol use with Sugargic MV 1mg/500mg/0.3mg SR Tablets is inadvisable.
PregnancyCONSULT YOUR DOCTOR
The use of Sugargic MV 1mg/500mg/0.3mg SR tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the advantages against possible risks prior to prescription. Seek medical advice.
Breast feedingCONSULT YOUR DOCTOR
The extended-release Sugargic MV 1mg/500mg/0.3mg tablet likely poses a risk during lactation. Available human data indicate potential drug transfer to breast milk, potentially harming the infant.
DrivingCAUTION
Driving ability can be impaired by both hypoglycemia and hyperglycemia. Refrain from driving if you experience these conditions.
KidneyUNSAFE
The use of Sugargic MV 1mg/500mg/0.3mg SR tablets carries a high risk of harm for individuals with kidney impairment and should be strictly avoided. Patients with severe kidney disease are especially advised against its use. Medical consultation is recommended.
LiverCAUTION
Patients with liver impairment should use Sugargic MV 1mg/500mg/0.3mg SR tablets cautiously, as dose modification may be necessary. A physician's consultation is advised. Individuals with mild to moderate hepatic dysfunction typically begin treatment with a reduced Sugargic MV 1mg/500mg/0.3mg SR tablet dosage; however, its use is contraindicated in those with severe liver disease.
What if you forget to take Sugargic MV 1mg/500mg/0.3mg Tablet SR :
Should you forget to take a Sugargic MV 1mg/500mg/0.3mg Tablet SR, ingest it immediately upon remembering. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual dosing regimen. Avoid taking a double dose.
Facts to Know About Sugargic MV 1mg/500mg/0.3mg Tablet SR
| Label | Value |
|---|---|
| Developing Habits | No. |
| Treatment Category | Diabetes Management |
3,018 People bought this recently